SATURDAY, OCTOBER 1, 2016

Sabin Vaccine Institute launches vaccine discovery initiative

The Sabin Vaccine Institute Product Development Partnership announced on Monday the launch of its soil-transmitted helminth vaccine discovery program.

The program seeks to develop ascariasis and trichuriasis candidate vaccine antigens and combine them with existing hookworm and schistosomiasis vaccines that are currently developed by Sabin PDP. If this occurs, the resulting vaccine would cover all four major human helminth infections.

"I felt compelled to support efforts to develop a vaccine against the four most devastating parasitic worm infections because more than one billion innocent people, many of them small children, are unnecessarily plagued by these diseases," Dr. Gary K. Michelson, president of the Gary Karlin Michelson, M.D. Charitable Foundation, Inc., said. "I hope that rigorous research, studies and testing conducted by the Sabin PDP, along with additional investments, will eventually lead to meaningful discoveries."

The inclusion of ascariasis and trichuriasis candidate vaccine agents into the current research was made possible with support from the Michelson's Foundation.

"We are excited to add this momentous program to the Sabin PDP's existing portfolio of neglected tropical disease (NTD) vaccines," Dr. Peter Hotez, president of the Sabin Vaccine Institute, said. "This new initiative opens a potential way forward to alleviate the suffering of millions of people living in extreme poverty worldwide.